<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">100895309</journal-id>
<journal-id journal-id-type="pubmed-jr-id">27065</journal-id>
<journal-id journal-id-type="nlm-ta">Cytotherapy</journal-id>
<journal-id journal-id-type="iso-abbrev">Cytotherapy</journal-id>
<journal-title-group>
<journal-title>Cytotherapy</journal-title>
</journal-title-group>
<issn pub-type="ppub">1465-3249</issn>
<issn pub-type="epub">1477-2566</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29859773</article-id>
<article-id pub-id-type="pmc">6123269</article-id>
<article-id pub-id-type="doi">10.1016/j.jcyt.2018.04.003</article-id>
<article-id pub-id-type="manuscript">NIHMS972284</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Gene Therapy for Sickle Cell Disease: An Update</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Demirci</surname>
<given-names>Selami</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Uchida</surname>
<given-names>Naoya</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tisdale</surname>
<given-names>John F.</given-names>
</name>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
<aff id="A1">Molecular and Clinical Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland</aff>
</contrib-group>
<author-notes>
<corresp id="FN1"><label>*</label><bold>Corresponding author: John F Tisdale</bold>, Molecular and Clinical Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland. P: +1 (301) 402-6497, F: +1 (301) 496-8396, <email>johntis@mail.nih.gov</email></corresp>
<fn fn-type="COI-statement" id="FN3">
<p>
<bold>Disclosure of interest</bold>
</p>
<p>The authors have no commercial, proprietary, or financial interest in the products or companies described in this article.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>7</day>
<month>6</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>30</day>
<month>5</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>7</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>7</month>
<year>2019</year>
</pub-date>
<volume>20</volume>
<issue>7</issue>
<fpage>899</fpage>
<lpage>910</lpage>
<!--elocation-id from pubmed: 10.1016/j.jcyt.2018.04.003-->
<abstract>
<p id="P1">Sickle cell disease (SCD) is one of the most common life threatening monogenic diseases affecting millions of people worldwide. Allogenic hematopietic stem cell transplantation is the only known cure for the disease with high success rates but the limited availability of matched sibling donors and the high risk of transplantation-related side effects force the scientific community to envision additional therapies. <italic>Ex vivo</italic> gene therapy through globin gene addition has been investigated extensively, and is currently being tested in clinical trials which have begun reporting encouraging data. Recent improvements in our understanding of the molecular pathways controlling mammalian erythropoiesis and hemoglobin offer new and exciting therapeutic options. Rapid and substantial advances in genome engineering tools, particularly CRISPR/Cas9, have raised the possibility of genetic correction in induced pluripotent stem cells (iPSCs) as well as patient-derived hematopoietic stem and progenitor cells (HSPCs). However, these techniques are still in their infancy and safety/efficacy issues remain that must be addressed before translating these promising techniques into clinical practice.</p>
</abstract>
<kwd-group>
<kwd>Sickle cell anemia</kwd>
<kwd>genome engineering</kwd>
<kwd>BCL11A</kwd>
<kwd>gene addition</kwd>
<kwd>fetal globin</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>